About Us
Overview
Our History
Leadership Team
Partner
Portfolio Advisory Board
Media Center
Our Science
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Media
Company News
Media Releases
Video
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information (2552.HK)
Corporate Communications
Careers
Company Culture
Join Us
Contact Us
中
中
中
About Us
Overview
Our History
Leadership Team
Partner
Portfolio Advisory Board
Media Center
Our Science
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Media
Company News
Media Releases
Video
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information (2552.HK)
Corporate Communications
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Presentations
Science & Innovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Presentations
2022 ADA Poster
Dorzagliatin, a dual-acting glucokinase activator, improves insulin secretion and glucose sensitivity in glucokinase-maturity-onset diabetes of the young (GK-MODY) and recent-onset type 2 diabetes.
Read More
2022 ADA Poster
Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin.
Read More
2022 ADA Poster
Dorzagliatin Effect in Diabetes Remission (DREAM Study)
Read More
2021 ADA Poster
Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.
Read More
2021 ADA Poster
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)
Read More
2020 ADA Poster
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)
Read More
<<
<
1
2
3
4
5
>
>>
上一页
下一页
About Us
Overview
Our History
Leadership Team
Portfolio Advisory Board
Partner
Media center
Research & Development
Inovation
Dorzagliatin
mGluR5
Presentations
Peer Reviewed Publications
Media
Company News
Media Releases
Video
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Careers
Culture
Join Us
Products&Pipeline
Pipeline
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2025 Hua Medicine (Shanghai) Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x